Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Serelaxin Is Early Victim Of East Coast Snow Storm

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA postpones Feb. 13 advisory committee review of heart failure drug due to “unanticipated weather conditions” expected for the Washington, D.C. area, although the cardio-renal panel’s meeting on The Medicines Co.’s cangrelor will proceed as planned Feb. 12.

Advertisement

Related Content

Cangrelor’s Approval Prospects: FDA Reviewers Say Yes, Team Leader Says No
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
For Novartis, No Relax’in On Serelaxin: More Trials Likely
Hurricane Sandy Rains On User Fee Dates, Advisory Committees

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076816

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel